This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
RBS leads banks lower
The bailed-out bank is considering offloading Ulster Bank, which is now in the black, dampening Friday's euphoria.
Merger and acquisition activity still surrounds the pharma sector. Reckitt Benckiser is hoping to dispose of its pharm division, while GlaxoSmithKline is contemplating spinning off its health unit. Pfizer is due to report tomorrow and the US drug giant is still on the prowl.
Meanwhile, if any shareholders need mothering or care it’s the investors of Mothercare; the stock has taken yet another knock as both the finance director and the US suitor walked away from the firm.
Disappointing US data pulls down Dow
In the US, the Dow Jones is down 45 points at 16,914, after disappointing service and housing figures ensured the US trading session got off on the wrong foot. Traders are looking for any excuse to take money out of the equity market ahead of the Federal Reserve meeting on Wednesday. US reporting season continues with Herbalife after the closing bell tonight. The heath food company managed to rally after Bill Ackman’s torpedo presentation, but can its figures make the hedge funder manger eat his words?
Copper traders anticipate rise
High grade copper appears to be gearing up for an attack on the 330 cents per pound mark as traders anticipate strong manufacturing figures from China at the end of the week. The recent HSBC survey of China came in at an 18-month high, but I doubt Beijing will disagree.
Gold can’t seem to get away from the $1300 level. Tensions in Ukraine and the Middle East could provide a flight to quality rush but non-farm payrolls is likely to drive it lower again.
Upcoming US reports weigh on FX markets
The euro is putting up a good fight against the US dollar but it is still drifting towards $1.34. Wednesday will be the acid test for the single currency, when German CPI is released and the Federal Open Market Committee meets. I expect soft German inflation figures will set the tone and the Fed's statement will ensure a move below $1.34.
Sterling is eyeing the $1.7 mark but traders don’t have the appetite as this week is more dollar-focused, due to the aforementioned Fed meeting and the jobs report on Friday. The UK’s growth is not to be ignored, however; the pound is expected to continue to hit new multi-year highs versus the greenback.